医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Biomatters to Launch WebApp Development Group at BioIT World

2013年04月04日 PM09:25
このエントリーをはてなブックマークに追加


 

SAN FRANCISCO

The WebApp Development Group will collaborate with customers, building analysis pipelines and reporting engines implemented on scalable public and private cloud platforms. CTO Matthew Landry will relocate from New Zealand to head up the new operations.

Landry says the group brings expertise in designing usable interfaces for bioinformatics to the world of online genomics applications. “By combining desktop and mobile web design with intelligent interface design and by forming strong alliances with key genomics platform providers, we will truly democratize omics analysis.”

The group was formed after Landry’s team released the Molecular Profiler on Illumina’s BaseSpace in November last year and draws from the knowledge and skill of the New Zealand-based software engineering team, who remain dedicated to the continued success of Biomatters’ widely used sequence analysis software, Geneious.

Biomatters will demonstrate its applications at the annual Bio-IT World Conference and Expo in Boston, April 9th to 11th, including the new Melanoma Profiler, developed in collaboration with the University of Auckland, for the analysis of melanoma tumor exome data to identify associations between mutated genes, pathways and druggable targets.

About Biomatters

Biomatters develops applications that accelerate the creation, publication and application of knowledge from omic research, with a mission to translate genomic data into biological and clinical insights.

CONTACT

Biomatters
Matthew Landry is available for comment
dmlandry@biomatters.com
+1
707 969 7070

同じカテゴリーの記事 

  • ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial
  • PROTEINA Initiates Global Clinical Validation Project with Emory University School of Medicine, USA
  • AriBio 获得欧洲药品管理局对AR1001治疗阿尔茨海默病3期临床试验(POLARIS-AD)的授权
  • AriBio Receives EMA Phase 3 Clinical Trial Authorisation for AR1001 in Treatment of Alzheimer’s Disease (POLARIS-AD)
  • ReNAgadeセラピューティクス、GanNA Bioと糖鎖生物学に対するコミットメントを継続